Jefferies Financial Group Inc. Takes Position in Abivax SA Sponsored ADR $ABVX

Jefferies Financial Group Inc. bought a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 457,325 shares of the company’s stock, valued at approximately $38,827,000. Jefferies Financial Group Inc. owned 0.59% of Abivax at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ABVX. Octagon Capital Advisors LP raised its stake in Abivax by 3.0% during the 2nd quarter. Octagon Capital Advisors LP now owns 1,267,000 shares of the company’s stock worth $9,693,000 after buying an additional 37,000 shares during the period. Millennium Management LLC grew its stake in Abivax by 6.0% in the first quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock valued at $6,171,000 after acquiring an additional 56,235 shares during the period. Boothbay Fund Management LLC grew its stake in Abivax by 52.5% in the second quarter. Boothbay Fund Management LLC now owns 870,438 shares of the company’s stock valued at $6,659,000 after acquiring an additional 299,770 shares during the period. Aberdeen Group plc increased its holdings in shares of Abivax by 10.8% during the third quarter. Aberdeen Group plc now owns 787,417 shares of the company’s stock valued at $66,852,000 after acquiring an additional 76,901 shares in the last quarter. Finally, Saturn V Capital Management LP increased its holdings in shares of Abivax by 12.6% during the second quarter. Saturn V Capital Management LP now owns 622,479 shares of the company’s stock valued at $4,762,000 after acquiring an additional 69,553 shares in the last quarter. 47.91% of the stock is owned by institutional investors.

Abivax Stock Down 3.0%

ABVX stock opened at $109.33 on Monday. The firm has a market capitalization of $8.65 billion, a PE ratio of -26.16 and a beta of 1.00. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.03. Abivax SA Sponsored ADR has a twelve month low of $4.77 and a twelve month high of $148.83. The stock’s 50 day moving average is $121.24 and its 200-day moving average is $107.82.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings results on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The company had revenue of ($4.92) million during the quarter. Sell-side analysts expect that Abivax SA Sponsored ADR will post -2.83 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on ABVX. BTIG Research reiterated a “buy” rating and issued a $150.00 target price on shares of Abivax in a report on Wednesday, February 25th. Wall Street Zen lowered shares of Abivax from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Guggenheim restated a “buy” rating and set a $175.00 price objective on shares of Abivax in a report on Thursday, December 18th. Oppenheimer set a $131.00 price objective on shares of Abivax in a research note on Thursday, January 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $134.75.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.